Video Library

How My Nurse Navigator Helped Me
2019 Hero of Hope Patient Award winner Kirsten Arbon explains how her nurse navigator provided her with guidance, wisdom, and support during her cancer journey.
Supporting Families with the KM3 Project
2019 Hero of Hope Patient Award winner Kirsten Arbon discusses her non-profit, the KM3 Project, which provides financial support to patients with cancer who are parents of children under 18.
My Journey as an Expectant Mother Diagnosed with Cancer
2019 Hero of Hope Patient Award winner Kirsten Arbon speaks about her experience of being treated for cancer while pregnant, and offers advice to survivors and their loved ones.
Top 10 AONN+ Milestones
To commemorate the tenth anniversary of AONN+, leadership takes a look back at 10 of the association’s most significant accomplishments.
Overcoming Challenges to Molecular Biomarker Testing
Drs. Geoffrey Oxnard and Lauren Ritterhouse discuss the challenges in biomarker testing—tissue stewardship and complexity of biomarker tests and results—and ways to overcome these challenges—improved communication among all members of the cancer care team and simplification of biomarker test results to focus on actionable biomarkers.
Impact of Reimbursement for Biomarker Testing on Clinical Practice
Drs. Geoffrey Oxnard and Lauren Ritterhouse deliberate on ways reimbursement issues are impacting clinical practice, particularly CMS’s “14-Day Rule.”
Reimbursement Challenges and Solutions with Molecular Biomarker Testing
Drs. Geoffrey Oxnard and Lauren Ritterhouse consider the current landscape of reimbursement for molecular biomarker testing, the need to run FDA-approved tests, and the role of CMS and local Medicare providers in testing reimbursement.
Identifying and Solving Top Challenges to Oncology Biomarker Testing
Drs. David Rimm and Roy Herbst identify the top challenges in the area of biomarker testing as well as solutions to these challenges, including availability of sufficient tissue for a large number of biomarker assays, the time some biomarker tests require for completion, the need for a tight association of test results with clinical outcomes, and the development of companion diagnostics for certain immunotherapies.
Navigating the CMS 14-Day Rule in Biomarker Testing
Drs. David Rimm and Roy Herbst review the problems with the CMS “14-Day Rule” since some of the multigene panel biomarker tests require 21 days or longer to complete.
Financial Constraints to Molecular Biomarker Testing
Drs. David Rimm and Roy Herbst discuss the challenges of reimbursement by payers and the costs to pathology department of molecular biomarker testing, especially immunohistochemistry and DNA testing.
Best Practices in Oncology Biomarker Testing
Drs. Goeffrey Oxnard and Lauren Ritterhouse review the best practices to improve efficiencies in biomarker testing, including effective communication among the healthcare team, the pathologist, and the patient, as well as expediting processing in the pathology laboratory.
Creating a Paradigm for Biomarker Testing
Drs. Goeffrey Oxnard and Lauren Ritterhouse consider the advantages and disadvantages of liquid biopsies as an early screening tool for biomarker testing, and how to integrate various approaches into a biomarker testing paradigm.
Page 4 of 7
Results 37 - 48 of 81

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code